In our study, mutational analysis of TCGA ovarian cancer data has shown that a significant percentage of patients have mutations or dysregulated expression of CDKN2A, CDK4, CDK6, or CCND1 that would likely make them good candidates for CDK4/6 inhibitor therapy (Figure 1A). Here, CDK4 is linked to ovarian cancer.